miR-17-5p inhibits invasion and metastasis of hepatocellular carcinoma through targeting effect on AKT3

doi:10.3877/cma.j.issn.2095-3232.2018.02.016

Abstract

Abstract:

Objective

To explore the effect and mechanism of microRNA (miR)-17-5p on the invasion and metastasis of hepatocellular carcinoma (HCC) cells.

Methods

Expression of miR-17-5p in the normal human L-02 hepatocyte and QGY-7703 HCC cells was detected by RT-PCR. QGY-7703 HCC cells were transfected by miR-17-5p mimic and mimic control respectively. Influence of miR-17-5p on the invasion and metastasis ability of HCC cells was detected using Transwell assay and scratch test. Target gene of miR-17-5p was confirmed by bioinformatic analysis, and its expression in HCC cells was detected by Western blot. After siRNA silenced by target gene, the invasion and metastasis ability of HCC cells were observed. Comparison of microRNA in the two kinds of cells was conducted by t test.

Results

Expression level of miR-17-5p in HCC cells was 0.16±0.04, significantly lower than 1.01±0.19 in normal L-02 hepatocytes (t=-9.67, P<0.05). Number of trans-membrane cells and metastasis rate of HCC cells transfected by miR-17-5p mimic were respectively 36±4 and (5.37±0.15) mm/d, significantly lower than 62±7 and (7.50±0.01) mm/d of control group (t=-15.40, -32.00; P<0.05). Bioinformatic analysis showed that AKT3 was the key target gene of miR-17-5p, and the expression of AKT3 in HCC cells was obviously higher than that of normal hepatocyte. Number of trans-membrane cells and metastasis rate of HCC cells transfected by siRNA-AKT3 were respectively 13±3 and (4.13±0.15) mm/d, significantly lower than 58±3 and (7.23±0.25) mm/d of control group (t=-17.88, -53.69; P<0.05).

Conclusion

miR-17-5p inhibits the invasion and metastasis ability of HCC cells through targeting effect on AKT3.

Key words: Carcinoma, hepatocellular, miR-17-5p, AKT3, Neoplasm invasiveness, Cell migration

Weihao Kong, Kun Li, Cuicui Xiao, Jingxiong Hu, Zenan Huang, Qiangxing Chen, Jian Zhang. miR-17-5p inhibits invasion and metastasis of hepatocellular carcinoma through targeting effect on AKT3[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(02): 152-155.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2018.02.016

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2018/V07/I02/152

Figures/Tables 2

References 27

[1]	Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma[J]. Gut, 2018, 67(2):380-388.
[2]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222.
[3]	Yang N, Ekanem NR, Sakyi CA, et al. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics[J]. Adv Drug Deliv Rev, 2015(81):62-74.
[4]	Wang ZM, Wan XH, Sang GY, et al. miR-15a-5p suppresses endometrial cancer cell growth via Wnt/β-catenin signaling pathway by inhibiting WNT3A[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21):4810-4818.
[5]	Feng ZY, Xu XH, Cen DZ, et al. miR-590-3p promotes colon cancer cell proliferation via Wnt/β-catenin signaling pathway by inhibiting WIF1 and DKK1[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21):4844-4852.
[6]	Gabra MM, Salmena L. microRNAs and acute myeloid leukemia chemoresistance:a mechanistic overview[J]. Front Oncol, 2017(7):255.
[7]	Yang Y, Hu Z, Zhou Y, et al. The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers[J]. Oncotarget, 2017, 8(52):90197-90214.
[8]	Mjelle R, Sellaeg K, Saetrom P, et al. Identification of metastasis-associated microRNAs in serum from rectal cancer patients[J]. Oncotarget, 2017, 8(52):90077-90089.
[9]	Zhu WJ, Chen X, Wang YW, et al. MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway[J]. Oncotarget, 2017, 8(52):89631-89642.
[10]	Yokoi A, Yoshioka Y, Hirakawa A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer[J]. Oncotarget, 2017, 8(52):89811-89823.
[11]	Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer[J]. Nat Rev Genet, 2016, 17(12):719-732.
[12]	Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease[J]. Cell, 2008, 133(2):217-222.
[13]	Olive V, Li Q, He L. mir-17-92:a polycistronic oncomir with pleiotropic functions[J]. Immunol Rev, 2013, 253(1):158-166.
[14]	Bobbili MR, Mader RM, Grillari J, et al. OncomiR-17-5p:alarm signal in cancer?[J]. Oncotarget, 2017, 8(41):71206-71222.
[15]	Liu F, Zhang F, Li X, et al. Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes[J]. Oncotarget, 2017, 8(40):69125-69138.
[16]	Fuziwara CS, Kimura ET. Insights into regulation of the miR-17-92 cluster of miRNAs in cancer[J]. Front Med, 2015(2):64.
[17]	Tan W, Li Y, Lim SG, et al. miR-106b-25/miR-17-92 clusters:polycistrons with oncogenic roles in hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(20):5962-5972.
[18]	Concepcion CP, Bonetti C, Ventura A. The microRNA-17-92 family of microRNA clusters in development and disease[J]. Cancer J, 2012, 18(3):262-267.
[19]	Wang X, Liu S, Cao L, et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(49):86592-86603.
[20]	Cui S, Sun Y, Liu Y, et al. MicroRNA-137 has a suppressive role in liver cancer via targeting EZH2[J]. Mol Med Rep, 2017, 16(16):9494-9502.
[21]	Li Y, Li Y, Chen Y, et al. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis[J]. Cancer Cell Int, 2017(17):102.
[22]	Yang F, Yin Y, Wang F, et al. miR-17-5p promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway[J]. Hepatology, 2010, 51(5):1614-1623.
[23]	Liu D, Dong L, Liu Y, et al. A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(4):5039-5047.
[24]	Madhunapantula SV, Robertson GP. Targeting protein kinase-b3 (akt3) signaling in melanoma[J]. Expert Opin Ther Targets, 2017, 21(3):273-290.
[25]	Yang H, Zheng W, Shuai X, et al. MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma[J]. Oncotarget, 2015, 6(29):27736-27750.
[26]	Zhang Y, Huang W, Ran Y, et al. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3[J]. Tumour Biol, 2015, 36(11):8309-8316.
[27]	Ma Y, She XG, Ming YZ, et al. MicroRNA-144 suppresses tumorigenesis of hepatocellular carcinoma by targeting AKT3[J]. Mol Med Rep, 2015, 11(2):1378-1383.

Please choose a citation manager

Content to export